In a previous study, a humanized mouse model of NSCLC was established, which was administered twice weekly with the combination of mouse anti-PD-1 (TSR-042) and anti-LAG-3 (TSR-033); additionally, when tumor growth was monitored for 35 days, this model showed significant synergy and the elimination of tumor growth in most implanted mice (tumor growth inhibition [TGI] effect was 97%; coefficient of drug interaction [CDI] < 0.7), as well as significant increases in proliferating T cells and total CD8+ T cells in the spleen [66]. Here, PDCD1 is linked to neoplasm.